# Selinexor and Backbone Treatments of Multiple Myeloma Patients

> **NCT02343042** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Karyopharm Therapeutics Inc** · enrollment: 300 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Selinexor
- **DRUG:** Dexamethasone
- **DRUG:** Lenalidomide
- **DRUG:** Pomalidomide
- **DRUG:** Bortezomib
- **DRUG:** Daratumumab
- **DRUG:** Carfilzomib
- **DRUG:** Ixazomib
- **DRUG:** Elotuzumab
- **DRUG:** Clarithromycin
- **DRUG:** Belantamab Mafodotin
- **DRUG:** Mezigdomide

## Key facts

- **NCT ID:** NCT02343042
- **Lead sponsor:** Karyopharm Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-10
- **Primary completion:** 2027-04
- **Final completion:** 2027-04
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02343042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02343042, "Selinexor and Backbone Treatments of Multiple Myeloma Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02343042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*